ReviewEuropean journal of epidemiology2022
A comparison of statistical methods to predict the residual lifetime risk.
Review in European journal of epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Influence of Multiple Risk Factor Management on the Onset and Progression of Chronic Kidney Disease in Patients With Hypertension.Journal of the American Heart Association · 2025Article
- Lifetime risk of incident dementia and incident mild cognitive impairment in older adults.medRxiv : the preprint server for health sciences · 2025Article
- Article
- Dynamic Importance of Genomic and Clinical Risk for Coronary Artery Disease Over the Life Course.Circulation. Genomic and precision medicine · 2025Article
- MSGene: a multistate model using genetic risk and the electronic health record applied to lifetime risk of coronary artery disease.Nature communications · 2024Article
- Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study.BMJ (Clinical research ed.) · 2024Article
- Article
- Assessment of Lifetime Risk for Cardiovascular Disease: Time to Move Forward.Current cardiology reviews · 2024Review
- MSGene: Derivation and validation of a multistate model for lifetime risk of coronary artery disease using genetic risk and the electronic health record.medRxiv : the preprint server for health sciences · 2023Article
- Dynamic Importance of Genomic and Clinical Risk for Coronary Artery Disease Over the Life Course.medRxiv : the preprint server for health sciences · 2023Article
- Age of onset and cumulative risk of mental disorders: a cross-national analysis of population surveys from 29 countries.The lancet. Psychiatry · 2023Article
- The association of education and household income with the lifetime risk of incident atrial fibrillation: The Framingham Heart study.American journal of preventive cardiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lifetime risk measures the cumulative risk for developing a disease over one's lifespan. Modeling the lifetime risk must account for left truncation, the competing risk of death, and inference at a fixed age. In addition, statistical methods to predict the lifetime risk should account for covariate-outcome associations that change with age. In this paper, we review and compare statistical methods to predict the lifetime risk. We first consider a generalized linear model for the lifetime risk using pseudo-observations of the Aalen-Johansen estimator at a fixed age, allowing for left truncation. We also consider modeling the subdistribution hazard with Fine-Gray and Royston-Parmar flexible parametric models in left truncated data with time-covariate interactions, and using these models to predict lifetime risk. In simulation studies, we found the pseudo-observation approach had the least bias, particularly in settings with crossing or converging cumulative incidence curves. We illustrate our method by modeling the lifetime risk of atrial fibrillation in the Framingham Heart Study. We provide technical guidance to replicate all analyses in R.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.